Please login to the form below

Not currently logged in
Email:
Password:

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

FDA panel undermines Lilly and Incyte’s baricitinib hopes

But analysts think the drug faces an uphill battle now to win market share from Pfizer’s Xeljanz (tofacitinib), the first JAK inhibitor to reach the market for RA in the ... Taking on Xeljanz isn’t the only challenge for baricitinib, however, as it

Latest news

More from news
Approximately 18 fully matching, plus 35 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with

  • Brand leaders in RA will lose market share, predict rheumatologists

    JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. ... The EMA’ s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics